Literature DB >> 10504013

The relationship of mismatch negativity to quantitative EEG and morphological findings in schizophrenia.

E Kirino1, R Inoue.   

Abstract

The goal of the present study is to investigate the relationships of mismatch negativity (MMN) to other markers in schizophrenics; Quantitative EEG (QEEG), CT and psychopathological ratings. Thirty unmedicated patients (28.4+/-9.8 y, 20 M) including twenty neuroleptic-naive cases were divided into two groups before treatment; Group A consisted of ten patients with greater MMN amplitudes, while twenty patients with smaller ones were assigned to Group B. In QEEG, Group A showed a closer profile to healthy controls, indicating their function is less distorted. Group B showed greater power in slow wave, slow alpha and fast beta bands. Their greater slow wave may be implicated in cognitive impairment reflected by attenuated MMN as well as greater dilation in lateral ventricles and Sylvian fissures on CT. After pharmacological treatment with conventional neuroleptics, Group A's MMN decreased, whereas that of Group B increased. Furthermore, neuroleptics' EEG-effects observed in Group A were close to the reported profiles of healthy subjects, while those in Group B were distinct from them. Conclusively, MMN might have crucial associations to other measures underlying the brain pathology of schizophrenia. The diagnostic value of MMN as a trait-marker was discussed.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10504013     DOI: 10.1016/s0022-3956(99)00012-6

Source DB:  PubMed          Journal:  J Psychiatr Res        ISSN: 0022-3956            Impact factor:   4.791


  12 in total

1.  Memantine Effects On Sensorimotor Gating and Mismatch Negativity in Patients with Chronic Psychosis.

Authors:  Neal R Swerdlow; Savita Bhakta; Hsun-Hua Chou; Jo A Talledo; Bryan Balvaneda; Gregory A Light
Journal:  Neuropsychopharmacology       Date:  2015-06-11       Impact factor: 7.853

2.  Neurophysiological biomarkers informing the clinical neuroscience of schizophrenia: mismatch negativity and prepulse inhibition of startle.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Curr Top Behav Neurosci       Date:  2014

Review 3.  Future clinical uses of neurophysiological biomarkers to predict and monitor treatment response for schizophrenia.

Authors:  Gregory A Light; Neal R Swerdlow
Journal:  Ann N Y Acad Sci       Date:  2015-03-09       Impact factor: 5.691

4.  Automatic auditory processing deficits in schizophrenia and clinical high-risk patients: forecasting psychosis risk with mismatch negativity.

Authors:  Veronica B Perez; Scott W Woods; Brian J Roach; Judith M Ford; Thomas H McGlashan; Vinod H Srihari; Daniel H Mathalon
Journal:  Biol Psychiatry       Date:  2013-09-16       Impact factor: 13.382

5.  Validation of mismatch negativity and P3a for use in multi-site studies of schizophrenia: characterization of demographic, clinical, cognitive, and functional correlates in COGS-2.

Authors:  Gregory A Light; Neal R Swerdlow; Michael L Thomas; Monica E Calkins; Michael F Green; Tiffany A Greenwood; Raquel E Gur; Ruben C Gur; Laura C Lazzeroni; Keith H Nuechterlein; Marlena Pela; Allen D Radant; Larry J Seidman; Richard F Sharp; Larry J Siever; Jeremy M Silverman; Joyce Sprock; William S Stone; Catherine A Sugar; Debby W Tsuang; Ming T Tsuang; David L Braff; Bruce I Turetsky
Journal:  Schizophr Res       Date:  2014-10-23       Impact factor: 4.939

6.  Equivalent mismatch negativity deficits across deviant types in early illness schizophrenia-spectrum patients.

Authors:  Rachel A Hay; Brian J Roach; Vinod H Srihari; Scott W Woods; Judith M Ford; Daniel H Mathalon
Journal:  Biol Psychol       Date:  2015-01-17       Impact factor: 3.251

7.  Using biomarkers to inform diagnosis, guide treatments and track response to interventions in psychotic illnesses.

Authors:  Veronica B Perez; Neal R Swerdlow; David L Braff; Risto Näätänen; Gregory A Light
Journal:  Biomark Med       Date:  2014       Impact factor: 2.851

8.  Mismatch negativity at acute and post-acute phases of first-episode schizophrenia.

Authors:  Müge Devrim-Uçok; H Yasemin Keskin-Ergen; Alp Uçok
Journal:  Eur Arch Psychiatry Clin Neurosci       Date:  2008-04       Impact factor: 5.270

Review 9.  [Mismatch negativity in schizophrenia research. An indicator of early processing disorders of acoustic information].

Authors:  T Rosburg; I Kreitschmann-Andermahr; H Sauer
Journal:  Nervenarzt       Date:  2004-07       Impact factor: 1.214

10.  A Meta-Analysis of Mismatch Negativity in Schizophrenia: From Clinical Risk to Disease Specificity and Progression.

Authors:  Molly A Erickson; Abigail Ruffle; James M Gold
Journal:  Biol Psychiatry       Date:  2015-08-31       Impact factor: 13.382

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.